BioLineRx (BLRX) Asset Utilization Ratio (2024 - 2025)
BioLineRx (BLRX) posted Asset Utilization Ratio of 0.03 for Q4 2025, down 90.46% on a QoQ basis from 0.31 in Q3 2025, and down 95.37% year-over-year from 0.63 in Q4 2024.
BioLineRx (BLRX) has 2 years of Asset Utilization Ratio data on file, last reported at 0.03 in Q4 2025.
- In Q4 2025, Asset Utilization Ratio fell 95.37% year-over-year to 0.03; the TTM figure through Dec 2025 stood at 0.03 (down 95.37% YoY), while the FY2025 annual figure was 0.03, down 94.75% from the prior year.
- Asset Utilization Ratio eased to 0.03 in Q4 2025, from 0.31 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.63 in Q4 2024 and bottomed at 0.03 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.85 |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.03 |
| Sep 30, 2025 | 0.31 |
| Jun 30, 2025 | 0.40 |
| Mar 31, 2025 | 0.54 |
| Dec 31, 2024 | 0.63 |
| Sep 30, 2024 | 0.29 |